Loading...
Two more reports have emerged from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which concerns the treatment of “real-world” patients with major depression, including many with comorbidities. In Wave 1, 4041 patients received open-label citalopram. In Wave 2, those who failed to respond to, or were intolerant of, citalopram were randomized to sertraline, sustained-release bupropion, or extended-release venlafaxine or to citalopram augmentation with bupropion SR or buspirone (Journal Watch Psychiatry Apr 5 2006). Of those with drug intolerance or with no remission in Wave 2, 235 were randomized in Wave 3 to mirtazapine or nortriptyline; no differences were seen in tolerability or in remission rates (mirtazapine,…